@inproceedings{f1fe56be82bc48228ca8e3ba62deb327,
title = "In Situ photoimmunotherapy for advanced cutaneous melanoma",
abstract = "Currently there are no truly effective treatments for advanced melanoma (surgically unresectable stage III and IV). In situ photoimmunotherapy (ISPI) is a recently developed therapy based on physical and immunological principles that uses lasers in combination with immunostimulants to achieve clinically significant responses in advanced melanoma patients. Results from an ongoing phase I clinical trial suggest that this form of therapy has the highest response rate of any treatment known for advanced melanoma, and in a significant number of subjects, periods of prolonged remissions from the disease can be achieved. ISPI is therefore clearly one of the most promising forms of therapy for this disease and better understanding of the immunological and physical parameters of this treatment will lead to even better clinical results.",
keywords = "Imiquimod, Immunotherapy, Laser, Melanoma, Solid tumor therapy",
author = "Naylor, {Mark F.} and Nordquist, {Robert E.} and Teaque, {T. Kent} and Adelson, {David A.} and Perry, {Lisa A.} and Chen, {Wei R.}",
year = "2008",
doi = "10.1117/12.764970",
language = "English (US)",
isbn = "9780819470324",
series = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",
booktitle = "Biophotonics and Immune Responses III",
note = "Biophotonics and Immune Responses III ; Conference date: 21-01-2008 Through 21-01-2008",
}